Compare Mesoblast Limited (MESO) vs Vanguard Emerging Markets Stock Index Fund ETF (VWO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Mesoblast Limited vs Vanguard Emerging Markets Stock Index Fund ETF — how do they compare? Mesoblast Limited trades at $16.32 (market cap $2.17B), while Vanguard Emerging Markets Stock Index Fund ETF trades at $58.88. The key difference: Vanguard Emerging Markets Stock Index Fund ETF is trading nearer its 52-week high, Mesoblast Limited nearer its low. Which is the better fit depends on your goals.
| MESO | VWO | |
|---|---|---|
Market Cap | $2.17B | — |
Sector | Technology | — |
52-Week High | $20.96 | $61.24 |
52-Week Low | $12.88 | $49.54 |
Enterprise Value | $2.17B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MESO trades at $16.63, down 3.98% on the day, with a bullish technical outlook supported by moving averages. The company shows strong revenue growth with Ryoncil generating $115 million in annual revenue, though it remains unprofitable with a net loss of $102 million. Recent developments include positive Phase 3 trial progress and FDA BLA filings for new treatments.
Investment outlook balances promising pipeline progress against significant financial losses. The stock offers growth potential through commercial expansion but carries substantial risk from continued cash burn and regulatory hurdles. Analyst consensus leans bullish with 45% buy ratings, reflecting optimism about the company's transition to commercial-stage operations.
VWO trades at $57.93, up 0.16% today, with a bearish technical signal from moving averages and neutral oscillators. The ETF's low expense ratio of 0.06% and 2.4% dividend yield (The Motley Fool, 2026-06-29) appeal to cost-conscious investors. Recent news highlights strong capital inflows into emerging markets and comparisons with peers like EEM, emphasizing VWO's cost advantage and exposure to developing economies without heavy China reliance.
Outlook: VWO offers diversified emerging market access at low cost, but faces risks from geopolitical tensions and China's economic volatility. Investor sentiment is mixed, with technicals suggesting caution despite fundamental strengths in expense efficiency and yield.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Mesoblast Limited
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →About Vanguard Emerging Markets Stock Index Fund ETF
The fund employs an indexing investment approach designed to track the performance of the FTSE Emerging Markets All Cap China A Inclusion Index. It invests by sampling the index, meaning that it holds a broadly diversified collection of securities that, in the aggregate, approximates the index in terms of key characteristics.
Read more on VWO →
